Provention Bio Inc Quick Ratio (PRVB) starting from the fourth quarter 2022 to fourth quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Provention Bio Inc   (NASDAQ: PRVB)

Provention Bio Inc 's Quick Ratio

PRVB's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2022, Quick Ratio fell to 1.83 a new company low.

Within Major Pharmaceutical Preparations industry 316 other companies have achieved higher Quick Ratio than Provention Bio Inc in fourth quarter 2022. While Quick Ratio total ranking in the fourth quarter 2022 has deteriorated compared to the prior quarter from 584 to 1173.

Explain Quick Ratio?
How much Cash & cash equivalents PRVB´s has?
What are PRVB´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PRVB Quick Ratio (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4
Y / Y Current Liabilities Change 296.6 % 20.7 % 2.12 % 1.1 % 36.23 %
Y / Y Cash & cash equivalent Change 73.48 % 23.05 % -52.08 % -58.96 % -21.93 %
Quick Ratio MRQ 1.83 7.39 3.36 3.14 4.17
PRVB's Total Ranking # 1173 # 584 # 1091 # 580 # 490
Seq. Current Liabilities Change 259.86 % -0.14 % -7 % 18.67 % 9.52 %
Seq. Cash & cash equivalent Change -11.06 % 119.49 % -0.61 % -10.59 % -36.92 %



Quick Ratio fourth quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 317
Healthcare Sector # 570
Overall Market # 1173


Quick Ratio Statistics
High Average Low
52.1 12.49 1.83
(Sep 30 2018)   (Dec 31 2022)




Financial Statements
Provention Bio Inc 's Current Liabilities $ 90 Millions Visit PRVB's Balance sheet
Provention Bio Inc 's Cash & cash equivalent $ 165 Millions Visit PRVB's Balance sheet
Source of PRVB's Sales Visit PRVB's Sales by Geography


Cumulative Provention Bio Inc 's Quick Ratio

PRVB's Quick Ratio for the trailling 12 Months

PRVB Quick Ratio

 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months
Y / Y Current Liabilities TTM Growth 76.56 % 12.58 % 13.35 % 32.58 % 82.61 %
Y / Y Cash & cash equivalent TTM Growth -17.38 % -31.39 % -36.34 % -21.75 % 21.57 %
Quick Ratio TTM 3.1 4.5 4.34 5.32 6.63
Total Ranking TTM # 4527 # 716 # 888 # 4375 # 4283
Seq. Current Liabilities TTM Growth 67.53 % 4.5 % 0.55 % 0.31 % 6.82 %
Seq. Cash & cash equivalent TTM Growth 15.52 % 8.36 % -18.11 % -19.41 % -4.07 %

Quick ratio ranking by company, industry and sector >> Back to PRVB Financial Strength Comparisons >> Go to Compare PRVB Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q4 2022 to $90.39 millions, cumulative Quick Ratio decreased to 3.1 below the Provention Bio Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 577 other companies have achieved higher Quick Ratio than Provention Bio Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2022 from 716 to 4527.

Explain Quick Ratio?
How much Cash & cash equivalents PRVB´s has?
What are PRVB´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 578
Healthcare Sector # 1164
Within the Market # 4527


trailing twelve months Quick Ratio Statistics
High Average Low
20.31 10.24 1.38
(Mar 31 2019)   (Dec 31 2018)




Companies with similar Quick Ratio in the quarter ending Dec 31 2022, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2022 MRQ Cash & cash equivalentDec 31 2022 MRQ Current Liabilities
Virpax Pharmaceuticals Inc   5.02 $ 18.995  Millions$ 3.787  Millions
Adc Therapeutics Sa  4.92 $ 652.882  Millions$ 132.798  Millions
Sagimet Biosciences inc   4.84 $ 32.345  Millions$ 6.680  Millions
Unity Biotechnology Inc   4.83 $ 94.795  Millions$ 19.620  Millions
Vera Therapeutics Inc   4.80 $ 114.653  Millions$ 23.896  Millions
Hoth Therapeutics Inc   4.78 $ 6.638  Millions$ 1.388  Millions
Immunome Inc   4.76 $ 20.323  Millions$ 4.274  Millions
Enveric Biosciences Inc   4.73 $ 17.724  Millions$ 3.747  Millions
Evelo Biosciences Inc   4.73 $ 47.940  Millions$ 10.136  Millions
Corbus Pharmaceuticals Holdings Inc   4.68 $ 59.197  Millions$ 12.640  Millions
Decibel Therapeutics Inc   4.66 $ 104.561  Millions$ 22.442  Millions
Assembly Biosciences Inc   4.54 $ 91.610  Millions$ 20.169  Millions
Xoma Royalty Corporation  4.53 $ 57.826  Millions$ 12.756  Millions
Revance Therapeutics Inc   4.50 $ 340.707  Millions$ 75.682  Millions
Proqr Therapeutics N v   4.49 $ 106.148  Millions$ 23.645  Millions
Gracell Biotechnologies Inc   4.48 $ 211.420  Millions$ 47.156  Millions
Biovie Inc   4.47 $ 18.642  Millions$ 4.169  Millions
Neurosense Therapeutics Ltd  4.46 $ 7.126  Millions$ 1.598  Millions
Carisma Therapeutics Inc   4.44 $ 51.996  Millions$ 11.709  Millions
Karyopharm Therapeutics Inc   4.43 $ 279.031  Millions$ 63.036  Millions
Acurx Pharmaceuticals inc   4.42 $ 9.112  Millions$ 2.062  Millions
Galmed Pharmaceuticals Ltd   4.42 $ 14.530  Millions$ 3.290  Millions
Arbutus Biopharma Corp  4.40 $ 146.913  Millions$ 33.369  Millions
Trevena inc   4.39 $ 38.320  Millions$ 8.732  Millions
Tg Therapeutics Inc   4.39 $ 233.456  Millions$ 53.201  Millions
Repare Therapeutics Inc   4.37 $ 343.941  Millions$ 78.619  Millions
Merus N v   4.37 $ 345.090  Millions$ 78.926  Millions
Kiniksa Pharmaceuticals International Plc  4.36 $ 190.608  Millions$ 43.765  Millions
Lipella Pharmaceuticals Inc   4.35 $ 5.122  Millions$ 1.178  Millions
Quantum Cyber N v   4.33 $ 34.284  Millions$ 7.919  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.